ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,070.55
      1.20%
      US Tech 100
      17,100.00
      2.07%
      Dow Jones
      38,503.69
      0.69%
      Brent Oil
      87.485
      -0.09%
      Bitcoin
      66,709.64
      0.46%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC
      6. Amarantus Bioscience Holdings Inc (CE) (AMBS)

      7. Amarantus Bioscience Holdings Inc (CE) (AMBS) News

      AMBS

      Amarantus Bioscience (CE) (AMBS)

      Amarantus Bioscience Holdings Inc (CE)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:USOTC:AMBS
      DateTimeSourceHeadlineSymbolCompany
      09/09/20222:20PMEdgar (US Regulatory)Sec Staff Action/letter (sec Staff)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      04/18/20224:18PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      04/18/20224:14PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      10/09/20206:02AMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      10/05/20205:25PMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      10/05/20205:22PMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      07/10/20203:03PMInvestorsHub NewsWireTodos Medical Expands Extraction Reagent and ANDiS 350 Extraction Automation Capacity to Support COVID-19 Testing in the USAUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      01/30/20209:42AMInvestorsHub NewsWireAmarantus Acquires Majority Interest in CBD Wellness Company HemporiUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      01/10/20206:52AMEdgar (US Regulatory)Withdrawal of Offering Statement Under Regulation a (1-a-w)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      01/09/20205:13PMEdgar (US Regulatory)Amended Registration a Offering Under the Securities Act of 1933 (1-a/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      01/09/20205:06PMEdgar (US Regulatory)Registration a Offering Under the Securities Act of 1933 (1-a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      12/04/20198:17AMInvestorsHub NewsWireAmarantus Sub Elto Pharma Gets Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson's DiseaseUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      10/24/20199:52AMInvestorsHub NewsWireAmarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic ProductsUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      09/27/20193:49PMEdgar (US Regulatory)Registration a Offering Under the Securities Act of 1933 (1-a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/28/20199:51AMInvestorsHub NewsWireAmarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Legal Hemp IndustryUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      01/07/20198:00AMInvestorsHub NewsWireAmarantus Provides 2019 RoadmapUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      11/28/20187:30AMInvestorsHub NewsWireCoeptis Pharma Enters into Agreement to Acquire Elto PharmaUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      07/20/20187:31AMInvestorsHub NewsWireAmarantus Provides Corporate UpdateUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      07/09/20188:00AMInvestorsHub NewsWireMANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published inUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      06/11/20187:00AMInvestorsHub NewsWireMANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal ModelUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      06/07/20188:17AMInvestorsHub NewsWireAmarantus Provides Update on Elto Pharma Capital Formation PlanUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      06/05/20188:11AMInvestorsHub NewsWireMANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science AdvancesUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/30/20188:00AMInvestorsHub NewsWireAmarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/24/201811:00AMInvestorsHub NewsWireAmarantus to Present at LD Micro and The Reg A ConferenceUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/22/20186:00AMInvestorsHub NewsWireAmarantus Retains Weild & Co. to Advise on JOBS Act FundingUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/21/20187:58AMInvestorsHub NewsWireMANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal..USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/11/20187:00AMInvestorsHub NewsWireAmarantus Provides Business OverviewUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/04/20188:16AMInvestorsHub NewsWireAmarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood DiagnosticUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/03/20189:15AMInvestorsHub NewsWireMANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's NewUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
      05/01/201810:30AMInvestorsHub NewsWireElto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairm...USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
       Showing the most relevant articles for your search:USOTC:AMBS